Looks like Donald Trump is back in business!

[Manage your email subscriptions.]( Good day, Trader! Here are our top 4 trade ideas today. These setups look primed! Be the best prepared trader on the Street!  [MyMD Pharmaceuticals, Inc. (MYMD)*](- Cases of autoimmune disease continue to rise, even as economies shrink DWAC- Google Play Store approves Truth Social DAL- Up 4% in pre-market after positive guidance  TSM- Gaps higher on earnings, chip stocks in play *This is an Issuer-Paid Advertisement, See Disclosure Below  Sponsored By [MyMD Pharmaceuticals, Inc. (MYMD)*](- Cases of autoimmune disease continue to rise, even as economies shrink The market focuses on growth, that’s where the money goes, into sectors with the potential to provide increased revenues and return on investment. With rates rising and inflation rampant, tech is getting crushed because expected future returns are falling, and revenue growth is slowing if not falling. This type of market is where intelligent investors shine, where stock picking becomes important. Despite tech and overall markets pulling back, there are sectors of the market that are growing and certain biotech companies are outperforming. While speculative plays are not in favor right now, it’s important to look at growth in an industry. According to the Guardian, internationally, it is now estimated that cases of autoimmune diseases are rising by between 3% and 9% a year. That’s a growing market where let's say the one for computer chips is falling.  [MYMD’s]( primary drug is currently in Phase 2 clinical trials for treating autoimmune disease, and slowing the aging process.  MYMD-1® – which is being designed to treat not only the symptoms but also the causes of autoimmune diseases as well as to slow down the aging process! Remember that MYMD’s market cap is less than $100 million today. I have seen many examples where a successful outcome in the FDA process has drastically changed the valuation for a company into the billions. Also remember that MYMD has told investors that they anticipate the results of FDA Phase 2 trials before the end of the year – what an exciting time to be a shareholder!  Looking at the price chart, historically [MYMD]( has not stayed below $3 for long and is currently trading near MAJOR $2 support. There haven’t been many opportunities to get in at better prices in the name! [Click Here To FInd Out More About the Company Working to Significantly Increase Lifespan](  *This is an Issuer-Paid Advertisement, See Disclosure Below  Join Ben Sturgill [LIVE at 2pm ET Today]( as he reveals the [“PREPPER” Trading System]( Ben will reveal his to 2 BEST “[Prepper Picks](” trade ideas LIVE at [no cost](. This system finds killer trade ideas regardless of what the market is doing! Get his “best-case scenario” if the market skyrockets and his “worst-case scenario” if the market tanks. [Sign Up Today!]( Don’t miss this special event! Only a couple of hours to go! [Here is your direct link to the 360 Wall Street Chat Room](  DWAC- Google Play Store approves Truth Social DWAC is gapping over 11% higher this morning following yesterday’s reports in the after-hours that the Truth Social app was approved on the Google Play store. That’s a whole lot of new potential users with Android devices that may want access to what the former President has to say after being banned on Twitter. This stock can be volatile and is trading near its lowest levels in almost a year.  To the downside, there is potential support just below the $17 area from the after hours. Below that, there is a gap to fill at $15.96 if these reports prove to be false or the buyers don’t arrive after the open. To the upside there is a resistance level above $18. Above that, the next target would be prior resistance at $19.64 and then the $22 area. Last month this stock was trading above $24 so if things get going, there’s no reason it can’t trade all the way up there today or tomorrow. [Here is your direct link to the 360 Wall Street Chat Room](  DAL- Up 4% in pre-market after positive guidance  DAL reported earnings this morning, and although they missed on the top and bottom line, they announced they expect Q4 Total Revenue to be up somewhere from 5% to 9% from 2019 levels. They also said they were on track to achieve their 2024 financial targets of over $7 in EPS and $4 billion in free cash flow. That’s a lot of potential upside considering the stock was trading 100% higher in 2019. The market will now need to assess how likely it is that DAL’s guidance will come to fruition.  To the upside there is resistance from the last few days at $30.70. Above that the next targets would be $32, and then $34. To the downside there is a gap to fill at $29.21. [Here is your direct link to the 360 Wall Street Chat Room](  TSM- Gaps higher on earnings, chip stocks in play TSM beat on the top and bottom line.They announced 35% revenue growth in Q3 and that it would be cutting Capex by 10%. Considering how hard chip stocks have been getting hit (TSM is down over 50% this year and 20% since August), there could be significant bounce potential in this name.  To the upside there is a gap to fill at $67.35. Above that, the next significant potential target would be $70, and then there is another gap at $74 which was a MAJOR prior support level. To the downside there is a gap to fill at $64.11. [Here is your direct link to the 360 Wall Street Chat Room](  To Your Success! 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360.com](  © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions  *THIS IS AN ISSUER-PAID ADVERTISEMENT, SEE DISCLOSURE BELOW*ISSUER-PAID ADVERTISEMENT. MyMD, Inc. (“MYMD” or the “Company”) HAS PAID ORWILL PAY SHERWOOD VENTURES, LLC (“Sherwood”) TWENTY-THOUSAND DOLLARS USD PER MONTH FOR THREE MONTHS (THE “INITIAL TERM”) IN CASH, SHARES OF RESTRICTED COMMON STOCK WITH A VALUE OF ONE-HUNDRED-FIFTY THOUSAND DOLLARS, AND WARRANTS VALUED AT ISSUANCE OF SEVENTY-FIVE THOUSAND DOLLARS FOR MARKETING SERVICES INCLUDING COMMUNICATING TO THE PUBLIC ABOUT THE COMPANY THROUGH SHERWOOD’S AFFILIATE RAGINGBULL.COM, LLC (“RAGING BULL”), AMONG OTHERS. THIS ADVERTISEMENT IS PART OF THOSE ISSUER-PAID MARKETING SERVICES. FOR DETAILED COMPENSATION AND MORE INFORMATION, PLEASE SEE THE FULL DISCLOSURE LOCATED AT HTTPS://BOARDROOMINVESTING.COM/MYMD-DISCLAIMER. DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [(. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of [RagingBull.com](, LLC are paid in whole or in part by commission based on their sales of Services to subscribers. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.